Institut Pasteur

Other

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

Agence Nationale De Valorisation De La Recherche

Jacqueline Gruest

Luc Montagnier

Solange Chamaret

Jean-Claude Chermann

Francoise Barre-Sinoussi

Christine Rouzioux

Francoise Rey

Willy Rozenbaum

Claudine Axler-Blin

Charles Dauguet

Robert C Gallo

Mikulas Popovic

Marie-Therese Nugeyre

Francoise Brun-Vezinet

Mangalasseril G Sarngadharan

Francoise Vezinet-Brun

Marie-Theresa Nugeyre

Emile R Bisagni

Christian Rivalle

Francoise Wendling

Pierre Tambourin

Claire Ducrocq

G Sarngadharan

Mangalasseril G Sarngadhar

Jean C Chermann

Marie Theresa Nugeyre

Alain Civier

Rosette Lidereau

Francoise Vezinet-Bruil

This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.

Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1

The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.

Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1)

Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.

Antibody directed against HIV-1 P25 antigen

Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.

Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies

The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.

Methods and kits for detecting antibodies against an HIV variant

Protein compositions containing the p18 and p25 proteins of the lymphadenopathy virus are used for detecting antibodies in blood serum as indicative of infection by such virus. The proteins can be used in various conventional ways to perform immunoassays for the detection of the antibodies.

Oligopeptides comprising p18 protein of human immunodeficiency virus

Protein compositions containing proteins of the lymphadenopathy virus, which compositions are used for diagnosis of antibodies of such protein in biological fluids, especially blood serum, for the detection or absence of infection. Such compositions contain typically the p18, p13 and/or p25 proteins.

Antigen of a human retrovirus, namely p18 protein of human

Antibody detection of antibodies to viral proteins in serum

Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.

Human Immunodeficiency Virus (HIV) associated with Acquired Immunual

A retrovirus B-LAV associated with lymphadenopathies and with Acquire Immune Deficiency Syndrome, being adapted to B lymphocytes and capable of being continuously produced by continuous cell lines of B lymphoblastoid cells; continuous cell lines of B lymphoblastoid cells which produce the B-LAV retrovirus and a process for producing such cell lines are disclosed.

Retrovirus associated with lymphadenopathies and adapted to continuous

Human immunodeficiency viruses associated with Acquired Immune

The novel derivatives correspond to the general formula: ##STR1## in which R.sub.1 is a Y--(CH.sub.2).sub.n --NR.sub.4 R.sub.5 group, where Y represents a single bond or the group ##STR2## R.sub.4 and R.sub.5, identical or different, are hydrogen or an alkyl radical, preferably a lower alkyl, or again form together a ring which can include heteroatoms, in particular nitrogen atoms. n is a number ranging from 1 to 10, notably from 2 to 7, R.sub.2 is a hydrogen atom, a lower alkyl group or an aralkyl group in which the alkyl substituent is a lower alkyl group, and R.sub.3 is a hydrogen atom or a CH.sub.3 group useful for the treatment of leukemias.

Pyrido (4,3-B) carbazoles substituted in the 1 position by a polyamine

Growing community of inventors

L'Hay les Roses, France

Jacqueline Gruest